{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:05:04Z","timestamp":1791288304142,"version":"4.3.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.urolonc.2012.02.008","type":"journal-article","created":{"date-parts":[[2012,7,3]],"date-time":"2012-07-03T12:16:41Z","timestamp":1341317801000},"page":"1457-1463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: Implications for prior therapy in clinical trials"],"prefix":"10.1016","volume":"31","author":[{"given":"Gregory R.","family":"Pond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Galsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance","family":"Leopold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2012.02.008_bib1","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2012.02.008_bib2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomized open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2012.02.008_bib3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2012.02.008_bib4","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab vs. zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomized, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.urolonc.2012.02.008_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0959-8049(11)70100-9","article-title":"Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA) [abstract 1LBA]","volume":"47","author":"Parker","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2012.02.008_bib6","unstructured":"Press release Medivation and Astellas; 3 November 2011."},{"key":"10.1016\/j.urolonc.2012.02.008_bib7","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1200\/JCO.2009.25.9259","article-title":"Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer","volume":"28","author":"Danila","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.02.008_bib8","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","article-title":"Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer","volume":"27","author":"Attard","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.02.008_bib9","doi-asserted-by":"crossref","first-page":"7992","DOI":"10.1158\/0008-5472.CAN-10-0585","article-title":"Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer","volume":"70","author":"Zhu","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2012.02.008_bib10","doi-asserted-by":"crossref","first-page":"8386","DOI":"10.1158\/0008-5472.CAN-09-1504","article-title":"Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer","volume":"69","author":"Gan","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2012.02.008_bib11","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/1078-0432.CCR-11-0728","article-title":"Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants","volume":"17","author":"Mostaghel","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2012.02.008_bib12","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1158\/0008-5472.CAN-11-0532","article-title":"Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is up-regulated by treatment with CYP17A1 inhibitors","volume":"71","author":"Cai","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2012.02.008_bib13","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1210\/endo.142.11.8467","article-title":"Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state","volume":"142","author":"Murillo","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.urolonc.2012.02.008_bib14","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1200\/JCO.2004.06.037","article-title":"Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583)","volume":"22","author":"Small","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.02.008_bib15","article-title":"Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer","author":"Sonpavde","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2012.02.008_bib16","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1158\/1078-0432.CCR-07-1036","article-title":"A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis","volume":"13","author":"Armstrong","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2012.02.008_bib17","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.02.008_bib18","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1200\/JCO.2009.24.1281","article-title":"Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy","volume":"28","author":"Ryan","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.02.008_bib19","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomized open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2012.02.008_bib20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ccr.2005.01.027","article-title":"Androgen ablation mitigates tolerance to a prostate\/prostate cancer-restricted antigen","volume":"7","author":"Drake","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2012.02.008_bib21","doi-asserted-by":"crossref","first-page":"14565","DOI":"10.1073\/pnas.251140998","article-title":"T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer","volume":"98","author":"Mercader","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.urolonc.2012.02.008_bib22","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"issue":"Suppl","key":"10.1016\/j.urolonc.2012.02.008_bib23","article-title":"Axitinib vs. sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial","volume":"29","author":"Rini Bi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.02.008_bib24","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1073\/pnas.1014480108","article-title":"Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma","volume":"108","author":"Keunen","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.urolonc.2012.02.008_bib25","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1172\/JCI24612","article-title":"Rapid vascular regrowth in tumors after reversal of VEGF inhibition","volume":"116","author":"Mancuso","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.urolonc.2012.02.008_bib26","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","volume":"15","author":"Ebos","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2012.02.008_bib27","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"P\u00e0ez-Ribes","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2012.02.008_bib28","first-page":"4438","article-title":"Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo","volume":"55","author":"Raffo","year":"1995","journal-title":"Cancer Res"},{"issue":"Suppl","key":"10.1016\/j.urolonc.2012.02.008_bib29","first-page":"18s","article-title":"A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401","volume":"28","author":"Kelly","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.02.008_bib30","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.2010.32.8815","article-title":"Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol vs. docetaxel plus prednisone for patients with castration-resistant prostate cancer","volume":"29","author":"Scher","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.02.008_bib31","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143912000610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143912000610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:02:25Z","timestamp":1761040945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143912000610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S1078143912000610"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2012.02.008","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: Implications for prior therapy in clinical trials","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2012.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}